RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Rating of “Buy” from Brokerages

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have been assigned a consensus recommendation of “Buy” from the ten analysts that are covering the stock, Marketbeat reports. Ten investment analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have issued a report on the stock in the last year is $38.18.

A number of research firms recently issued reports on RAPT. HC Wainwright reissued a “buy” rating and set a $41.00 target price on shares of RAPT Therapeutics in a research report on Monday, August 14th. JPMorgan Chase & Co. reduced their price objective on RAPT Therapeutics from $39.00 to $32.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 16th. Stifel Nicolaus began coverage on RAPT Therapeutics in a report on Tuesday, August 8th. They set a “buy” rating and a $40.00 price target on the stock. Berenberg Bank assumed coverage on RAPT Therapeutics in a report on Thursday. They set a “buy” rating and a $34.00 price target on the stock. Finally, Piper Sandler raised their target price on RAPT Therapeutics from $28.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, August 14th.

Insider Transactions at RAPT Therapeutics

In related news, insider William Ho sold 2,500 shares of the firm’s stock in a transaction that occurred on Friday, August 18th. The stock was sold at an average price of $18.92, for a total value of $47,300.00. Following the transaction, the insider now directly owns 21,289 shares of the company’s stock, valued at approximately $402,787.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. FMR LLC grew its holdings in shares of RAPT Therapeutics by 50.9% during the 1st quarter. FMR LLC now owns 4,455,840 shares of the company’s stock worth $81,765,000 after purchasing an additional 1,503,626 shares in the last quarter. Braidwell LP bought a new stake in shares of RAPT Therapeutics during the fourth quarter worth $19,800,000. State Street Corp grew its holdings in shares of RAPT Therapeutics by 159.5% during the third quarter. State Street Corp now owns 1,273,891 shares of the company’s stock worth $30,650,000 after purchasing an additional 783,026 shares during the last quarter. Perceptive Advisors LLC lifted its stake in shares of RAPT Therapeutics by 27.4% during the first quarter. Perceptive Advisors LLC now owns 2,291,608 shares of the company’s stock valued at $42,051,000 after acquiring an additional 492,653 shares during the period. Finally, Deep Track Capital LP lifted its stake in RAPT Therapeutics by 75.9% in the second quarter. Deep Track Capital LP now owns 1,004,561 shares of the company’s stock valued at $18,785,000 after buying an additional 433,328 shares during the period. 99.09% of the stock is owned by institutional investors.

RAPT Therapeutics Trading Up 1.5 %

Shares of RAPT stock opened at $19.50 on Friday. The firm has a 50-day moving average price of $21.03 and a 200 day moving average price of $20.50. RAPT Therapeutics has a twelve month low of $15.59 and a twelve month high of $31.45. The company has a market capitalization of $670.02 million, a price-to-earnings ratio of -7.25 and a beta of 0.40.

RAPT Therapeutics (NASDAQ:RAPT) last announced its earnings results on Friday, August 11th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.12. As a group, research analysts predict that RAPT Therapeutics will post -2.95 earnings per share for the current year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.